Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia
Merck KGaA to try again to get approval for MS pill cladribine
Modulation of the Innate Immune Response by Human Neural Precursors Prevails Over Oligodendrocyte Progenitor Remyelination to Rescue a Severe Model Of Pelizaeus-Merzbacher Disease.
Teva and Active Biotech Announce Expansion of Laquinimod Clinical Development Program with New Trial in Primary Progressive Multiple Sclerosis and First Patient Screened in Huntington's Disease Trial
Teva and Active Biotech Announce First Patient Enrolled in Phase II Study Evaluating Laquinimod for Primary Progressive MS
Long term benefit of multiple sclerosis treatment: an investigation using a novel data collection technique.
Cognitive Impairment in Multiple Sclerosis.
Cerebrospinal Fluid BAFF and APRIL Levels in Neuromyelitis Optica and Multiple Sclerosis Patients During Relapse.
Is the treatment of multiple sclerosis headed in the wrong direction?
Default network activity is a sensitive and specific biomarker of memory in multiple sclerosis.
A population based cohort study to assess the safety of pandemic influenza vaccine Focetria(®) in Emilia-Romagna region, Italy-Part Two.
Tumefactive demyelinating lesions during etanercept treatment requiring decompressive hemicraniectomy.
MRI Mapping of Cerebrovascular Reactivity via Gas Inhalation Challenges.
Four different synthetic peptides of proteolipid protein induce a distinct antibody response in MP4-induced experimental autoimmune encephalomyelitis.
Immune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: results from a double-blind placebo-controlled study.
Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids.
[The role of brain glucose metabolism in the development of cognitive dysfunctions in patients with remitting and secondary-progressive multiple sclerosis.]
ATP increases the migration of microglia across the brain endothelial cell monolayer.
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.
Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein.
Increased B cell and cytotoxic NK cell proportions and increased T cell responsiveness in blood of natalizumab-treated multiple sclerosis patients.
Hematopoietic stem cell transplantation for multiple sclerosis: is it a clinical reality?
Interleukin-17- and interleukin-22-secreting myelin-specific CD4(+) T cells resistant to corticoids are related with active brain lesions in multiple sclerosis patients.
Type 1 immune response in progressive multiple sclerosis.
Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms.

Pages